GlassScriptPhysician profile
Alan S Cleland
NPI 1932182227
$21,889.70
in general payments reported to CMS, 2019-2025
70 companies · $3,281 in 2025
The $3,281 reported for 2025 was more than what 84% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,193 · 2020: $2,484 · 2021: $3,230 · 2022: $3,239 · 2023: $3,368 · 2024: $3,094 · 2025: $3,281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,732 · Education: $12.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,731.71 |
| Education | $12.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,492.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $1,564.41 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $1,537.68 | 2019-2025 | |
| Insulet Corporation | $1,362.64 | 2019-2025 | Omnipod |
| Mannkind Corporation | $1,217.18 | 2019-2024 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $1,177.66 | 2019-2024 | Farxiga |
| Lilly USA, LLC | $1,135.76 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Dexcom, INC. | $954.18 | 2019-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $885.60 | 2019-2025 | Evenity, Tepezza, Prolia |
| Radius Health, INC. | $875.00 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $793.58 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $753.76 | 2019-2025 | Jardiance |
| Antares Pharma, INC. | $662.12 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Ibsa Pharma INC. | $503.32 | 2019-2025 | Tirosint, Licart, Licart |
| Abbvie INC. | $495.33 | 2019-2025 | Synthroid |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $476.31 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $438.48 | 2019-2023 | Steglatro, Steglujan |
| Horizon Therapeutics Plc | $305.54 | 2020-2023 | Tepezza |
| Amarin Pharma, INC. | $297.49 | 2019-2022 | |
| Corcept Therapeutics | $292.99 | 2019-2024 | Korlym |
| Medtronic, INC. | $241.42 | 2021-2025 | Minimed 780g, Inceptiv, Intellis Adaptivestim |
| Ascendis Pharma Endocrinology INC | $241.38 | 2023-2025 | Yorvipath |
| Bayer Healthcare Pharmaceuticals INC. | $217.11 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $215.31 | 2021-2025 | Strensiq |
| Endo Pharmaceuticals INC. | $211.84 | 2019-2022 | |
| Beta Bionics, INC. | $211.02 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Vivus LLC | $153.45 | 2019-2024 | Qsymia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.57 | 2019-2021 | |
| Cequr Corporation | $130.62 | 2024-2025 | Cequr Simplicity |
| Lifescan, INC. | $127.80 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $122.80 | 2025 | |
| Janssen Pharmaceuticals, INC | $121.88 | 2019-2020 | |
| Recordati_rare_diseases_inc. | $111.24 | 2021-2025 | Isturisa |
| Sequel Med Tech, LLC | $93.89 | 2025 | Twiist |
| Averitas Pharma INC. | $91.36 | 2024-2025 | Qutenza |
| Eisai INC. | $82.22 | 2019-2024 | |
| Endo USA, INC. | $74.39 | 2025 | Xiaflex, Aveed |
| Zealand Pharma US, INC. | $72.14 | 2021-2022 | |
| Kyowa Kirin, INC. | $70.45 | 2024-2025 | Crysvita |
| Pfizer INC. | $67.22 | 2022-2024 | |
| Halozyme INC | $61.43 | 2023 | |
| Astellas Pharma US INC | $57.40 | 2023-2025 | Veozah |
| Clarus Therapeutics INC. | $53.66 | 2021 | |
| Grt US Holding, INC. | $50.53 | 2022 | |
| Shire North American Group INC | $49.54 | 2019 | |
| Novartis Pharmaceuticals Corporation | $48.20 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $45.59 | 2019-2020 | |
| Eusa Pharma (US) LLC | $45.34 | 2022 | |
| Almatica Pharma LLC | $44.23 | 2024-2025 | Teriparatide |
| Tolmar, INC. | $37.19 | 2025 | Jatenzo |
| Soleno Therapeutics, INC. | $35.17 | 2025 | Vykat Xr |
| Azurity Pharmaceuticals, INC. | $33.80 | 2023 | Adthyza |
| Acella Pharmaceuticals, LLC | $31.19 | 2023-2025 | NP Thyroid 60 |
| Medtronic Minimed, INC. | $28.60 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $26.56 | 2020-2021 | |
| Chiesi USA, INC. | $23.57 | 2025 | Mycapssa |
| Madrigal Pharmaceuticals | $21.51 | 2024 | Resmetirom |
| Acerus Pharmaceuticals Corporation | $19.91 | 2021 | |
| Amneal Pharmaceuticals LLC | $19.57 | 2025 | Unithroid |
| Inspire Medical Systems, INC. | $19.37 | 2024 | Inspire |
| Companion Medical, INC. | $18.73 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $18.28 | 2023 | Crysvita |
| Verity Pharmaceuticals INC. | $16.30 | 2025 | Tlando |
| Amryt Pharma Holdings LTD | $15.17 | 2021 | |
| Nestle Healthcare Nutrition INC. | $14.57 | 2022 | |
| Ascensia Diabetes Care US INC. | $13.15 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $12.63 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Cleland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.